Evidence map›Paper›PMID 38283731›Full record

ArticleJCEM case reports2024

A Case of an Ectopic ACTH-Producing Tumor With Adrenal Shrinkage During Osilodrostat Administration.

Fumikazu Sawabe, Ryo Hayafusa, Rieko Kosugi, Hiroyuki Ariyasu

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Medical Treatment of Cushing's Syndrome.Endocrinology and metabolism (Seoul, Korea) · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fumikazu SawabeCenter for Diabetes, Endocrinology and Metabolism, Shizuoka General Hospital, Shizuoka City, 420-8527, Japan.ORCID https://orcid.org/0009-0008-9834-0228
Ryo HayafusaCenter for Diabetes, Endocrinology and Metabolism, Shizuoka General Hospital, Shizuoka City, 420-8527, Japan.
Rieko KosugiCenter for Diabetes, Endocrinology and Metabolism, Shizuoka General Hospital, Shizuoka City, 420-8527, Japan.
Hiroyuki AriyasuCenter for Diabetes, Endocrinology and Metabolism, Shizuoka General Hospital, Shizuoka City, 420-8527, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ectopic adrenocorticotropin (ACTH)-secreting tumors are among the causes of ACTH-dependent Cushing syndrome. When surgical resection of the primary lesion is not feasible, medications such as metyrapone, mitotane, and ketoconazole have been used to control hypercortisolism. This report presents a case treated with the novel drug osilodrostat, wherein the patient's adrenal glands exhibited shrinkage following the initiation of this drug. The case involves a 68-year-old man diagnosed with small cell lung cancer and ectopic ACTH-producing Cushing syndrome. Initially, metyrapone was administered to manage hypercortisolism, but its effect proved insufficient. Subsequently, osilodrostat was initiated while gradually decreasing metyrapone, leading to full suppression of blood cortisol levels. With continued osilodrostat treatment, the adrenal glands reduced in size, suggesting the potential to reduce the osilodrostat dosage.

Indexed as

adrenal shrinkageCushing syndromeectopic ACTH-producing tumorosilodrostat

Identifiers

PMID38283731
PMCPMC10821766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.